Xenogeneic/JJ
human/JJ
serum/NN
promotes/VBZ
leukocyte/NN
adhesion/NN
to/TO
porcine/NN
endothelium/NN
under/IN
flow/NN
conditions/NNS
,/,
possibly/RB
through/IN
the/DT
activation/NN
of/IN
the/DT
transcription/NN
factor/NN
NF-kappa/NN
B/NN
./.

Endothelial/JJ
cell/NN
activation/NN
and/CC
leukocyte/NN
infiltration/NN
are/VBP
a/DT
consistent/JJ
feature/NN
of/IN
discordant/JJ
xenograft/NN
rejection/NN
./.
=====
Here/RB
we/PRP
evaluated/VBD
whether/IN
xenogeneic/JJ
serum/NN
,/,
as/IN
a/DT
source/NN
of/IN
xenoreactive/JJ
natural/JJ
antibodies/NNS
and/CC
complement/NN
,/,
induced/VBD
endothelial/JJ
cell/NN
activation/NN
with/IN
consequent/JJ
leukocyte/NN
adhesion/NN
under/IN
flow/NN
conditions/NNS
./.
=====
Porcine/JJ
aortic/JJ
endothelial/JJ
cells/NNS
(/(
PAEC/NNS
)/)
were/VBD
incubated/VBN
for/IN
1/CD
hr/NN
30/CD
min/NN
or/CC
5/CD
hr/NN
with/IN
10/CD
%/NN
homologous/JJ
porcine/JJ
serum/NN
(/(
control/NN
)/)
or/CC
10/CD
%/NN
xenogeneic/JJ
human/JJ
serum/NN
and/CC
then/RB
perfused/VBN
with/IN
total/JJ
human/JJ
leukocytes/NNS
in/IN
a/DT
parallel/NN
plate/NN
flow/NN
chamber/NN
under/IN
laminar/JJ
flow/NN
(/(
1.5/CD
dynes/cm2/NNS
)/)
./.
=====
Adherent/JJ
cells/NNS
were/VBD
counted/VBN
by/IN
digital/JJ
image/NN
analysis/NN
./.
=====
Xenogeneic/JJ
human/JJ
serum/NN
significantly/RB
(/(
P/NN
</JJR
0.01/CD
)/)
increased/VBD
the/DT
number/NN
of/IN
adherent/JJ
leukocytes/NNS
as/IN
compared/VBN
with/IN
porcine/JJ
serum/NN
./.
=====
A/DT
similar/JJ
adhesive/JJ
response/NN
was/VBD
elicited/VBN
by/IN
TNF/NN
alpha/NN
(/(
100/CD
U/ml/NN
)/)
,/,
one/CD
of/IN
the/DT
most/RBS
potent/JJ
inducers/NNS
of/IN
endothelial/JJ
cell/NN
adhesive/JJ
properties/NNS
,/,
here/RB
used/VBN
as/IN
positive/JJ
control/NN
./.
=====
In/IN
order/NN
to/TO
elucidate/VB
possible/JJ
mechanisms/NNS
underlying/VBG
endothelial/JJ
cell/NN
activation/NN
by/IN
xenogeneic/JJ
serum/NN
,/,
we/PRP
focussed/VBD
on/IN
transcription/NN
factor/NN
NF-kappa/NN
B/NN
,/,
a/DT
central/JJ
regulator/NN
for/IN
the/DT
induction/NN
of/IN
different/JJ
genes/NNS
,/,
including/VBG
adhesive/JJ
molecules/NNS
and/CC
chemoattractants/NNS
./.
=====
By/IN
confocal/JJ
fluorescence/NN
microscopy/NN
,/,
we/PRP
observed/VBD
a/DT
positive/JJ
staining/NN
for/IN
NF-kappa/NN
B/NN
(/(
p65/NN
subunit/NN
)/)
in/IN
the/DT
nuclei/NNS
of/IN
PAEC/NNS
exposed/VBN
for/IN
1/CD
hr/NN
30/CD
min/NN
to/TO
human/JJ
serum/NN
,/,
which/WDT
indicated/VBD
NF-kappa/NN
B/NN
activation/NN
in/IN
this/DT
setting/NN
./.
=====
At/IN
variance/NN
,/,
in/IN
PAEC/NNS
incubated/VBN
with/IN
the/DT
homologous/JJ
serum/NN
,/,
NF-kappa/NN
B/NN
was/VBD
strictly/RB
localized/JJ
in/IN
the/DT
cell/NN
cytoplasm/NN
./.
=====
Treatment/NN
of/IN
PAEC/NNS
exposed/VBN
to/TO
xenogeneic/JJ
serum/NN
with/IN
the/DT
NF-kappa/NN
B/NN
inhibitors/NNS
pyrrolidinedithiocarbamate/NN
(/(
PDTC/NN
,/,
25/CD
microM/NN
)/)
and/CC
tosyl-phechloromethylketone/NN
(/(
TPCK/NN
,/,
25/CD
microM/NN
)/)
significantly/RB
(/(
P/NN
</JJR
0.01/CD
)/)
reduced/VBD
leukocyte/NN
adhesion/NN
in/IN
respect/NN
to/TO
PAEC/NNS
treated/VBN
with/IN
human/JJ
serum/NN
alone/RB
./.
=====
Findings/NNS
that/IN
xenogeneic/JJ
serum/NN
promotes/VBZ
leukocyte-endothelium/JJ
interaction/NN
possibly/RB
through/IN
NF-kappa/NN
B/NN
activation/NN
might/MD
be/VB
relevant/JJ
for/IN
designing/VBG
future/JJ
therapeutic/JJ
strategies/NNS
aimed/VBN
at/IN
prolonging/VBG
xenograft/NN
survival/NN
./.